Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation
Hematological Oncology · 2026
DOI: 10.1002/hon.70212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2026. Verfasst von Linlin Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Myelodysplastic Syndromes, Splicing Factor U2AF, Mutation. Die Arbeit nennt 41 Literaturangaben. Gefördert von: CAMS Initiative Fund for Medical Sciences, National Natural Science Funds, Tianjin Natural Science Funds.
Abstract (Originalsprache)
RUNX1 is one of the most commonly mutated genes in myelodysplastic neoplasms (MDS) and essential for hematopoiesis. However, clinical phenotype features of RUNX1 mutated patients and the interaction between RUNX1 and other genes mutations remains incompletely explored. We enrolled 1473 consecutive adult patients with primary MDS to investigate the laboratory, genomic characteristics, and survival of RUNX1 ‐mutated MDS subjects. We found that RUNX1 mutations are associated with older age (median, 59 vs. 56 years, p = 0.007), lower platelet counts (median, 50 × 10 9 /L vs. 66 × 10 9 /L; p < 0.001), higher bone marrow blasts (median, 6.0% vs. 2.5%, p < 0.001) and a higher proportion of micro‐megakaryocytes (median, 26.0% vs. 18.7%, p < 0.001). Additionally, our data showed a correlation between the variant allele frequency (VAF) of RUNX1 mutations and proportion of micro‐megakaryocytes ( r = 0.242, p = 0.006), suggesting RUNX1 mutations burden was associated with dysmegakaryopoiesis. Mutations in ASXL1 , SRSF2 , EZH2 and NRAS were significantly more frequent in RUNX1 ‐mutated patients compared with those without RUNX1 mutations (adjusted p < 0.05). RUNX1 ‐mutated patients exhibited poorer overall survival (median OS 18 months vs. 51 month, p < 0.001), while U2AF1 co‐mutations were associated with a relatively better prognosis (median OS 34 months vs. 17 months, p = 0.003), indicating a potential modifying effect of U2AF1 on the outcome of RUNX1 ‐mutated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, China.
ORCID-Profile: Linlin Liu, Bing Li, Zhijian Xiao
Förderung
- CAMS Initiative Fund for Medical Sciences
- National Natural Science Funds
- Tianjin Natural Science Funds
Zitieren
APA
Liu, L., Li, B., Qin, T., Xu, Z., Qu, S., Pan, L., Gao, Q., Jiao, M., Bao, Z., Liu, N., Jia, Y., Li, C., & Xiao, Z. (2026). Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation. Hematological Oncology. https://doi.org/10.1002/hon.70212
Vancouver
Liu L, Li B, Qin T, Xu Z, Qu S, Pan L, et al. Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation. Hematological Oncology. 2026. doi:10.1002/hon.70212
BibTeX
@article{Liu2026,
author = {Liu, Linlin and Li, Bing and Qin, Tiejun and Xu, Zefeng and Qu, Shiqiang and Pan, Lijuan and Gao, Qingyan and Jiao, Meng and Bao, Zefei and Liu, Ningning and Jia, Yujiao and Li, Chengwen and Xiao, Zhijian},
title = {Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation},
journal = {Hematological Oncology},
year = {2026},
doi = {10.1002/hon.70212}
}
EUVIMED